Australia's most trusted
source of pharma news
Posted 28 June 2024 AM
Prostate cancer patient groups are the most dissatisfied with pharma compared to advocacy groups representing other cancer types, according to a deep dive into the latest PatientView survey, with the blame pointing to a lack of dedication by companies to find treatments for the disease.
A comparison of what blood, breast, lung and prostate cancer patient groups say about pharma companies, threw up significantly different rankings but across three out of four metrics prostate cancer patient groups gave industry the poorest scores.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.